NASDAQ:CRTXCortexyme Stock Price, Forecast & News

Cortexyme's stock was trading at $37.02 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CRTX stock has increased by 19.9% and is now trading at $44.39.
View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cortexyme in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cortexyme.

Cortexyme is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020.
View our earnings forecast for Cortexyme.

Cortexyme, Inc. (NASDAQ:CRTX) announced its quarterly earnings data on Tuesday, May, 12th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.45) by $0.16.
View Cortexyme's earnings history.

3 equities research analysts have issued 12 month price objectives for Cortexyme's shares. Their forecasts range from $59.00 to $76.00. On average, they expect Cortexyme's stock price to reach $68.33 in the next year. This suggests a possible upside of 53.9% from the stock's current price.
View analysts' price targets for Cortexyme.

Media coverage about CRTX stock has trended positive this week, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cortexyme earned a media sentiment score of 2.8 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future.
View the latest news about Cortexyme.

Cortexyme saw a decrease in short interest in the month of July. As of July 31st, there was short interest totaling 1,550,000 shares, a decrease of 7.7% from the July 15th total of 1,680,000 shares. Based on an average daily volume of 150,300 shares, the days-to-cover ratio is currently 10.3 days. Currently, 13.0% of the shares of the company are short sold.
View Cortexyme's Short Interest.

Some companies that are related to Cortexyme include Cerner (CERN), Omnicell (OMCL), HMS (HMSY), Allscripts Healthcare Solutions (MDRX), Vocera Communications (VCRA), HealthStream (HSTM) and Computer Programs & Systems (CPSI).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cortexyme investors own include Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Zosano Pharma (ZSAN), BioNano Genomics (BNGO), DHT (DHT), EnLink Midstream (ENLC), Golar LNG Partners (GMLP) and Matinas BioPharma (MTNB).

(CRTX) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 4,400,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

Cortexyme trades on the NASDAQ under the ticker symbol "CRTX."

Cortexyme's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include EPIQ Capital Group LLC (11.36%), Alps Advisors Inc. (0.14%), SG Americas Securities LLC (0.13%), Swiss National Bank (0.11%), UBS Group AG (0.08%) and New York State Common Retirement Fund (0.05%). Company insiders that own Cortexyme stock include David Lamond, Epiq Capital Group, Llc and Pfizer Inc.
View institutional ownership trends for Cortexyme.

CRTX stock was sold by a variety of institutional investors in the last quarter, including Alps Advisors Inc., UBS Group AG, and Virtus ETF Advisers LLC.
View insider buying and selling activity for Cortexyme.

CRTX stock was acquired by a variety of institutional investors in the last quarter, including EPIQ Capital Group LLC, SG Americas Securities LLC, Swiss National Bank, Letko Brosseau & Associates Inc., Virtu Financial LLC, Strs Ohio, Principal Financial Group Inc., and State Board of Administration of Florida Retirement System. Company insiders that have bought Cortexyme stock in the last two years include David Lamond, Epiq Capital Group, Llc, and Pfizer Inc.
View insider buying and selling activity for Cortexyme.

Shares of CRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CRTX stock can currently be purchased for approximately $44.39.

Cortexyme has a market capitalization of $1.31 billion. The biopharmaceutical company earns $-36,980,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis. Cortexyme employs 16 workers across the globe.

The official website for Cortexyme is www.cortexyme.com.

Cortexyme's mailing address is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 415-910-5717 or via email at [email protected]